Corrections
What counts as an error, how fast we fix it, how fixes are marked, and every material correction we’ve made.
The short answer
Found something wrong? Tell us with the form below. We check every report against the original source, aim to fix confirmed errors within 7 days, and list every material correction on this page.
On this page
What counts as an error?
Anything on a page that a reliable source contradicts.
- A wrong or out-of-date fact: a price, dose, date, number, approval, recall or rule.
- A claim our source doesn’t support, or a fact credited to the wrong body, such as a UK rule described as an EU one.
- A source link that’s broken or points to the wrong document.
- A translation that changes what the source says.
Not errors: a rule that differs between countries (each country version follows its own regulator), or a view on which medicine suits you. We don’t give personal advice. Typos and clumsy wording we fix quietly, but please still tell us.
What do you do with a report?
We check it against the original source and fix what’s wrong, everywhere it appears.
- We read your report and open the source behind the sentence, plus yours if you gave one.
- If the page is wrong, we fix it on every country and language version with the same mistake.
- We aim to fix confirmed errors within 7 days of your report, and faster when it affects safety.
- If you left an email, we reply with what we changed, or with the source that shows the page was right.
How are corrections marked?
A material correction gets a dated note on the page and an entry in the log below.
A correction is material when it changes something a reader might act on: a number, a price, a dose, a rule, or who said what. The note sits above the page’s sources and reads like this: “Correction, 14 Nov 2026: this page said X. It now says Y.” The page’s “Updated” date changes too.
Typos, wording that doesn’t change the meaning, and broken links swapped for the same source don’t get a note.
Report an error
Tell us the page, the sentence and what’s wrong. A source helps us fix it faster.
Corrections log
Every material correction, newest first. Each entry shows what the page said and what it says now.
-
Saudi Arabia
GLP‑1 forms in Saudi Arabia: three more pages left out capsules
- What was wrong
- Two guides described a GLP‑1 medicine as “a weekly injection or a daily tablet”, and the Foundayo article asked whether there are “other GLP‑1 tablets” in Saudi Arabia, as if Foundayo were a tablet.
- What it says now
- A weekly injection, or a tablet or capsule each day; the article now asks about other GLP‑1 medicines taken by mouth. In Saudi Arabia Foundayo (orforglipron) is registered as hard capsules (SFDA drugs list, register no. 1907260142, checked 14 Oct 2026). In the US, UK and UAE it is a film‑coated tablet, so those pages are unchanged.
-
Saudi Arabia
Registered GLP‑1 forms in Saudi Arabia: capsules were missing
- What was wrong
- The pages said the GLP‑1 medicines registered in Saudi Arabia come only as pens or tablets.
- What it says now
- Pens, tablets or capsules. The SFDA drugs list also has Foundayo (orforglipron) hard capsules, 1 to 36 mg (SFDA drugs list, checked 14 Oct 2026), registered in August 2026 (SFDA news, 2 Aug 2026).
-
United States
People the Medicare GLP‑1 Bridge excludes: plan coverage stated too firmly
- What was wrong
- The pages said people with type 2 diabetes, moderate-to-severe sleep apnea or MASH “go through their Part D plan” instead of the Bridge, which read as if their plan would cover a GLP‑1.
- What it says now
- They can’t use the Bridge, and Medicare tells them to contact their own drug plan, which “may already cover” a GLP‑1, as Medicare’s Bridge fact sheet (CMS Product No. 12234, June 2026) says. The pages now cite that fact sheet.
-
United States
Medicare drug plans and Wegovy: the 2027 drug-list rule was missing
- What was wrong
- The page said Part D plans “may cover it but are not required to”, with no year. That holds for 2026 only.
- What it says now
- In 2026, plans may cover Wegovy’s heart use but are not required to. From January 1, 2027, every Part D plan must include Ozempic, Rybelsus and Wegovy in its drug list, because Medicare negotiated their price (CMS negotiated-price fact sheet, November 2025). Plans may still use prior authorization, and weight-only use stays excluded. The page now cites the CMS fact sheet.
-
India
Lirafit monthly price given as about ₹3,000
- What was wrong
- The home page price table gave Lirafit (Glenmark’s liraglutide) as about ₹3,000 a month at 1.2 mg, from Glenmark’s January 2024 launch figure of about ₹100 a day. That is not today’s MRP.
- What it says now
- The MRP is ₹2,085.94 an 18 mg pen, as listed by two pharmacies that agree (checked 5 October 2026): ₹2,086 a month at the 0.6 mg starting dose, ₹4,172 at 1.2 mg and ₹6,258 at 1.8 mg, matching our cost calculator.
-
United States
Urgent insurance appeals: one deadline given for every kind of plan
- What was wrong
- The page said an urgent appeal must be decided “no later than 4 business days” without saying which plans that applies to. That is HealthCare.gov’s wording for Marketplace plans; employer plans follow a different federal rule.
- What it says now
- Marketplace plans: as fast as your condition needs, and no later than 4 business days, per HealthCare.gov. Employer plans covered by ERISA, which includes most private employers’ plans: within 72 hours, under the Department of Labor’s claims rule (29 CFR 2560.503-1). The page now cites that rule.
-
Canada
Zepbound and Mounjaro price at 12.5 and 15 mg given as not published
- What was wrong
- The pages said we had found no published Canadian price for tirzepatide (Zepbound, Mounjaro) at 12.5 or 15 mg, and sourced the lower doses’ prices to a news report.
- What it says now
- Canada’s Drug Agency reviews SR0920 (Zepbound) and SR0886 (Mounjaro) give the maker’s submitted price: $540 per 12.5 or 15 mg pen of 4 weekly doses, about $7,020 a year, alongside $300 at 2.5 and 5 mg and $420 at 7.5 and 10 mg. The pages now cite those reviews, and match our cost calculator.
-
United States
Medicaid coverage of GLP‑1s for weight loss given as 13 states
8 pages
Does Medicaid cover Wegovy in my state? · Does Medicaid cover Wegovy or Zepbound? Which states cover GLP‑1s for weight, and which dropped them · Is Wegovy covered for heart protection or fatty liver (MASH) when weight loss isn’t? · Getting a prescription in the US, and the medicines · Should I consider a GLP-1 medicine? And when not to · Choosing where to get a GLP-1 in the US: doctor, telehealth or clinic · Someone in my family might need a GLP-1. How do I help? · I'm thinking about a GLP-1 for my weight. Where do I start?- What was wrong
- The pages gave KFF’s January 2026 count of 13 state Medicaid programs covering GLP‑1s for weight loss as the current number. One page also said KFF doesn’t name the 13 states; KFF’s Figure 1 map does.
- What it says now
- As of October 14, 2026, 10 states cover them: Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia and Wisconsin. Utah (June 30), Massachusetts (July 3) and Rhode Island (October 1) ended coverage in 2026. The pages link our new state-by-state Medicaid list, which gives each state’s own source.